Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) EBITDA Margin (2016 - 2019)

Phio Pharmaceuticals' EBITDA Margin history spans 8 years, with the latest figure at 10219.05% for Q1 2019.

  • For Q1 2019, EBITDA Margin fell 48427.0% year-over-year to 10219.05%; the TTM value through Dec 2019 reached 42795.24%, down 3745901.0%, while the annual FY2024 figure was 2954.8%, 11731187.0% up from the prior year.
  • EBITDA Margin reached 10219.05% in Q1 2019 per PHIO's latest filing, down from 2617.54% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 2617.54% in Q3 2018 to a low of 24611.11% in Q2 2016.
  • Average EBITDA Margin over 5 years is 11855.58%, with a median of 9976.92% recorded in 2018.
  • Peak YoY movement for EBITDA Margin: tumbled -1378529bps in 2016, then tumbled -48427bps in 2019.
  • A 5-year view of EBITDA Margin shows it stood at 8664.71% in 2015, then crashed by -184bps to 24611.11% in 2016, then surged by 46bps to 13273.33% in 2017, then skyrocketed by 80bps to 2617.54% in 2018, then tumbled by -290bps to 10219.05% in 2019.
  • Per Business Quant, the three most recent readings for PHIO's EBITDA Margin are 10219.05% (Q1 2019), 2617.54% (Q3 2018), and 3274.14% (Q2 2018).